Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trialsNicola A. Hanania, John G. Matthews, Petr Kopecký et al.|The Lancet Respiratory Medicine|2016Cited by 465
Shadow cost of oral corticosteroids-related adverse events: A pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registryGiorgio Walter Canonica, Massimo Triggiani, Giorgio Lorenzo Colombo et al.|World Allergy Organization Journal|2019Cited by 119